Parallel Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Parallel Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.74K	Buy	59 +38	+181%	+$1.82K	﹤0.01%	3439
2026 Q1	$1.08K	Sell	21 -75	-78%	-$3.82K	﹤0.01%	3531
2025 Q4	$4.77K	Buy	96 +73	+317%	+$3.55K	﹤0.01%	2862
2025 Q3	$1.1K	Sell	23 -9	-28%	-$362	﹤0.01%	3198
2025 Q2	$1.01K	Buy	32 +20	+167%	+$641	﹤0.01%	3190
2025 Q1	$393	Hold	12	–	–	﹤0.01%	3274
2024 Q4	$434	Hold	12	–	–	﹤0.01%	3246
2024 Q3	$374	Hold	12	–	–	﹤0.01%	3223
2024 Q2	$321	Hold	12	–	–	﹤0.01%	3148
2024 Q1	$409	Hold	12	–	–	﹤0.01%	3086
2023 Q4	$347	Sell	12 -56	-82%	-$1.49K	﹤0.01%	3107
2023 Q3	$1.88K	Buy	68 +15	+28%	+$457	﹤0.01%	2842
2023 Q2	$1.59K	Hold	53	–	–	﹤0.01%	2816
2023 Q1	$1.92K	Hold	53	–	–	﹤0.01%	2792
2022 Q4	$1.89K	Sell	53 -8	-13%	-$278	﹤0.01%	2704
2022 Q3	$2K	Buy	+61	New	+$1.99K	﹤0.01%	2759
2020 Q4	–	Sell	-76	Closed	-$2K	–	2713
2020 Q3	$2K	Hold	76	–	–	﹤0.01%	2348
2020 Q2	$1K	Buy	+76	New	+$1.68K	﹤0.01%	2373

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Parallel Advisors's SUPN Position: Q2 2026 in Review

Parallel Advisors increased its Supernus Pharmaceuticals (SUPN) stake by 181% in Q2 2026, buying an estimated $1.82K and bringing the position to 59 shares worth $2.74K. The position accounts for ﹤0.01% of the portfolio, ranked #3439.

Parallel Advisors first reported a position in SUPN in Q2 2020 and has held it in 18 quarters since. The position peaked at $4.77K in Q4 2025. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Parallel Advisors held 59 shares of Supernus Pharmaceuticals worth $2.74K as of Q2 2026.
Parallel Advisors bought 38 Supernus Pharmaceuticals shares in Q2 2026, an estimated $1.82K.
Supernus Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3439 holding.
Parallel Advisors first reported a position in Supernus Pharmaceuticals in Q2 2020 and has held it in 18 quarters since.
Parallel Advisors's Supernus Pharmaceuticals position peaked at $4.77K in Q4 2025.
334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.